Noble Capital Out Positive on Tonix Pharma (TNXP) Following FDA Update, 'We continue to expect product approval on or before August 15, 2025'
Tweet Send to a Friend
Noble Capital analyst Robert LeBoyer reiterated an Outperform rating and $70.00 price target on Tonix Pharma (NASDAQ: TNXP).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
